

Admedus Ltd ABN 35 088 221 078 REGISTERED OFFICE: 26 Harris Road Malaga Western Australia 6090 PO Box 6879 East Perth Western Australia 6892 **T** +61 (0)8 9266 0100 **F** +61 (0)8 9266 0199

1 July 2015

F +61 (0)8 9266 0199
 E info.au@admedus.com

www.admedus.com

Centralised Company Announcements Platform Australian Stock Exchange 10th floor, 20 Bond Street Sydney NSW 2000

Dear Sir / Madam,

#### Appendix 3B – Exercise of Options

The Board of Directors of Admedus Ltd (ASX: AHZ) hereby announces that the Company has allotted 18,650,000 unlisted \$0.117 options expiring 30 June 2020 to new employees and executives under the Employee Share Option Plan.

Refer to the attached Appendix 3B.

Yours sincerely For and on behalf of Admedus Limited

Blann

Stephen Mann Company Secretary

*Rule 2.7, 3.10.3, 3.10.4, 3.10.5* Appendix 3B

#### New issue announcement,

#### application for quotation of additional securities

#### and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

ADMEDUS LIMITED

ABN

2

35 088 221 078

We (the entity) give ASX the following information.

#### Part 1 - All issues

issued

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued

Number of +securities issued or

to be issued (if known) or maximum number which may be

Ordinary shares fully paid

18,650,000 exp 30/06/2020

Unlisted \$0.117 options expiring 30 June 2020

3 Principal terms of the \*securities (eg, if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)

<sup>+</sup> See chapter 19 for defined terms.

4 Do the \*securities rank equally in all respects from the date of allotment with an existing \*class of quoted \*securities?

If the additional securities do not rank equally, please state:

Yes

Nil

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 5 Issue price or consideration
- 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)
- Sign-on and executive options issued under ESOP

6a Is the entity an <sup>+</sup>eligible entity that has obtained security holder approval under rule 7.1A?

> If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

- 6b The date the security holder resolution under rule 7.1A was passed
- 6c Number of \*securities issued without security holder approval under rule 7.1
- 6d Number of \*securities issued N with security holder approval under rule 7.1A

7	Yes
ľ	
ı	
2	
l	

14 November 2014

N/A

N/A

<sup>+</sup> See chapter 19 for defined terms.

6f Number of securities issued under an exception in rule 7.2

6g If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.

6h If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

 Dates of entering \*securities into uncertificated holdings or despatch of certificates

8 Number and <sup>+</sup>class of all <sup>+</sup>securities quoted on ASX (*including* the securities in section 2 if applicable)

+Class	
Ordinary Shares	

18,850,000 (Exemption 9)

N/A

N/A

30 June 2015

Listing Rule 7.1 capacity: 79,584,855

Listing Rule 7.1A capacity: 167,389,903

+ See chapter 19 for defined terms.

		Number	+Class
9	Number and <sup>+</sup> class of all	4,100,000	05/11/19
	<sup>+</sup> securities not quoted on ASX		\$0.21 options
	(including the securities in		
	section 2 if applicable)	15,000,000	21/05/19
			\$0.17 options
		2,000,000	1/2/19
		2,000,000	\$0.245 options
			¢onz ie options
		3,000,000	01/07/18
			\$0.17 options
		9,000,000	16/12/18 © 27 and include
			\$0.27 options
		15,050,067	18/06/18
		10,000,007	\$0.095 options
		2,000,000	01/03/18
			\$0.06 options
		0 100 004	10/05/17
		2,133,334	18/05/17 \$0.06 options
			\$0.00 options
		3,666,667	10/7/16
		- , ,	\$0.06 options
			_
		51,080,000	10/7/16
			\$0.06 options
		18,850,000	30/6/2020
		10,000,000	\$0.117 options
			\$0.117 Options

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A

#### Part 2 - Bonus issue or pro rata issue

- 11 Is security holder approval N/A required?
- 12 Is the issue renounceable or nonrenounceable?
- 13 Ratio in which the <sup>+</sup>securities will N/A be offered

J/A

N/A

·11 NT/A

<sup>+</sup> See chapter 19 for defined terms.

- <sup>+</sup>Class of <sup>+</sup>securities to which the 14 offer relates
- determine N/A \*Record date to 15 entitlements
- Will different N/A 16 holdings on registers (or subregisters) be aggregated for calculating entitlements?
- Policy for deciding entitlements N/A 17 in relation to fractions
- Names of countries in which the N/A 18 entity has +security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with.

Cross reference: rule 7.7.

Closing date for receipt of N/A 19 acceptances or renunciations

N/A

+ See chapter 19 for defined terms.

20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders	N/A
25	If the issue is contingent on +security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
		L
30	How do <sup>+</sup> security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do <sup>+</sup> security holders sell <i>part</i> of their entitlements through a	N/A

broker and accept for the balance?

N/A			

32 How do <sup>+</sup>security holders dispose of their entitlements (except by sale through a broker)?

33 <sup>+</sup>Despatch date

N/A			

N/A

#### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34	Type of securities ( <i>tick one</i> )
(a)	Securities described in Part 1
(b)	All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

## Additional securities forming a new class of securities

Tick to docum	e you are providing the information or	
	If the traduction are toquity convition	tha

35	If the *securities are *equity securities, the names of the 20 largest holders of the
	additional +securities, and the number and percentage of additional +securities
	held by those holders
	 N/A
36	If the *securities are *equity securities, a distribution schedule of the additional
	<sup>+</sup> securities setting out the number of holders in the categories
	1 - 1,000
	1,001 - 5,000
	5,001 - 10,000
	10,001 - 100,000
	100,001 and over
	 N/A
37	A copy of any trust deed for the additional <sup>+</sup> securities
	N/A

<sup>+</sup> See chapter 19 for defined terms.

# Entities that have ticked box 34(b)

38	Number of securities for which <sup>+</sup> quotation is sought	N/A	
39	Class of <sup>+</sup> securities for which quotation is sought	N/A	
40	Do the <sup>+</sup> securities rank equally in all respects from the date of allotment with an existing <sup>+</sup> class of quoted <sup>+</sup> securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	N/A	
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security)	N/A	
42	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the securities in clause 38)	Number N/A	+Class N/A

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- 1 <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the <sup>+</sup>securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those <sup>+</sup>securities should not be granted <sup>+</sup>quotation.
  - An offer of the <sup>+</sup>securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any <sup>+</sup>securities to be quoted and that noone has any right to return any <sup>+</sup>securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before <sup>+</sup>quotation of the <sup>+</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

ann .....

Sign here:

Date: 1 July 2015

Company secretary

Print name:

..Stephen Mann.....

Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for $^+$ eligible entities

Introduced 01/08/12

## Part 1

Rule 7.1 – Issues exceeding 15% of capital Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
Add the following:			
<ul> <li>Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul>	149,610,177		
<ul> <li>Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</li> </ul>	83,200,937		
<ul> <li>Number of partly paid ordinary securities that became fully paid in that 12 month period</li> </ul>	0		
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>			
<b>Subtract</b> the number of fully paid ordinary securities cancelled during that 12 month period	Nil		
"A"	1,673, 899,035		

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
<i>Multiply</i> "A" by 0.15	251,084,855
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule
<i>Insert</i> number of equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	171,500,000
Under an exception in rule 7.2	
Under rule 7.1A	
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>	
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable ) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	171,500,000
Step 4: Subtract "C" from ["A" x " placement capacity under rule 7.1 "A" x 0.15 Note: number must be same as shown in Step 2	
Subtract "C"	171,500,000
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	79,584,855
	[Note: this is the remaining placement capacity under rule 7.1]

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	1,673,899,035	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<i>Multiply</i> "A" by 0.10	167,389,903	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
<i>Insert</i> number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil	
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"E"	Nil	

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10 Note: number must be same as shown in Step 2	167,389,903
<i>Subtract</i> "E" <i>Note: number must be same as shown in</i> <i>Step 3</i>	Nil
<i>Total</i> ["A" x 0.10] – "E"	167,389,903

Note: this is the remaining placement capacity under rule 7.1A